Clinical Trials Logo

Fabry's Disease clinical trials

View clinical trials related to Fabry's Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06019728 Recruiting - Fabry's Disease Clinical Trials

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

SHORTEN
Start date: November 10, 2023
Phase: Phase 4
Study type: Interventional

This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.

NCT ID: NCT04847713 Recruiting - Fabry's Disease Clinical Trials

Early Detection and Follow-Up of Patients With Fabry's Disease

Start date: January 1, 2021
Phase:
Study type: Observational

This research project will serve on the enhancement of early detection, diagnosis and follow-up of patients with Fabry Disease, through new biomarkers identification. This could have straight clinical impact on: 1. Early diagnosis, follow-up, and prediction of treatment response. 2. Suggestion about the optimal time to start treatment. 3. The data obtained will help to deepen our knowledge of the correlation among Lyso-Gb3, genotype and phenotype. 4. Better understanding of the pathophysiology of FD. To sum up, the results of the study will make a significant contribution to scientific knowledge providing new evidence with an immediate clinical application in FD patients. As well as, the project will serve as the basis for a large-scale project implementation to validate the results obtained

NCT ID: NCT02469181 Recruiting - Fabry's Disease Clinical Trials

Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy (RECAFTURE Trial)

Start date: May 21, 2015
Phase:
Study type: Observational

The purpose of this study is to evaluate the impact of ERT on LV diastolic function and flow in patients with Fabry's cardiomyopathy using diastolic stress echocardiography, LV vortex flow and CMR.